TY - JOUR
T1 - Genes Associated With Hypertrophic Cardiomyopathy
T2 - A Reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel
AU - Hespe, Sophie
AU - Waddell, Amber
AU - Asatryan, Babken
AU - Owens, Emma
AU - Thaxton, Courtney
AU - Adduru, Mhy-Lanie
AU - Anderson, Kailyn
AU - Brown, Emily E.
AU - Hoffman-Andrews, Lily
AU - Jordan, Elizabeth
AU - Josephs, Katherine
AU - Mayers, Megan
AU - Peters, Stacey
AU - Stafford, Fergus
AU - Bagnall, Richard D.
AU - Bronicki, Lucas
AU - Callewaert, Bert
AU - Chahal, C. Anwar A.
AU - James, Cynthia A.
AU - Jarinova, Olga
AU - Landstrom, Andrew P.
AU - McNally, Elizabeth M.
AU - Murray, Brittney
AU - Muiño-Mosquera, Laura
AU - Parikh, Victoria
AU - Reuter, Chloe
AU - Walsh, Roddy
AU - Wayburn, Bess
AU - Ware, James S.
AU - Ingles, Jodie
N1 - Publisher Copyright:
© 2025 American College of Cardiology Foundation
PY - 2025/2/25
Y1 - 2025/2/25
N2 - Background: Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition affecting ∼1 in 500 and exhibits marked genetic heterogeneity. Previously published in 2019, 57 HCM-associated genes were curated providing the first systematic evaluation of gene-disease validity. Objectives: The authors report work by the Clinical Genome Resource Hereditary Cardiovascular Disease (HCVD) Gene Curation Expert Panel (GCEP) to reappraise the clinical validity of previously curated and new putative HCM genes. Methods: The Clinical Genome Resource systematic gene curation framework was used to reclassify the gene-disease relationships for HCM and related syndromic entities involving left ventricular hypertrophy. Genes previously curated were included if their classification was not definitive, and if the time since curation was >2 to 3 years. New genes with literature assertions for HCM were included for initial evaluation. Existing genes were curated for new inheritance patterns where evidence existed. Curations were presented on twice monthly calls, with the HCVD GCEP composed of 29 individuals from 21 institutions across 6 countries. Results: Thirty-one genes were recurated and an additional 5 new potential HCM-associated genes were curated. Among the recurated genes, 17 (55%) genes changed classification: 1 limited and 4 disputed (from no known disease relationship), 9 disputed (from limited), and 3 definitive (from moderate). Among these, 3 (10%) genes had a clinically relevant upgrade, including TNNC1, a 9th sarcomere gene with definitive HCM association. With new evidence, 2 genes were curated for multiple inheritance patterns (TRIM63, disputed for autosomal dominant but moderate for autosomal recessive; ALPK3, strong for autosomal dominant and definitive for recessive). CSRP3 was curated for a semidominant mode of inheritance (definitive). Nine (29%) genes were downgraded to disputed, further discouraging clinical reporting of variants in these genes. Five genes recently reported to cause HCM were curated: RPS6KB1 and RBM20 (limited), KLHL24 and MT-TI (moderate), and FHOD3 (definitive). Conclusions: We report 29 genes with definitive, strong, or moderate evidence of causation for HCM or isolated left ventricular hypertrophy, including sarcomere, sarcomere-associated, and syndromic conditions.
AB - Background: Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition affecting ∼1 in 500 and exhibits marked genetic heterogeneity. Previously published in 2019, 57 HCM-associated genes were curated providing the first systematic evaluation of gene-disease validity. Objectives: The authors report work by the Clinical Genome Resource Hereditary Cardiovascular Disease (HCVD) Gene Curation Expert Panel (GCEP) to reappraise the clinical validity of previously curated and new putative HCM genes. Methods: The Clinical Genome Resource systematic gene curation framework was used to reclassify the gene-disease relationships for HCM and related syndromic entities involving left ventricular hypertrophy. Genes previously curated were included if their classification was not definitive, and if the time since curation was >2 to 3 years. New genes with literature assertions for HCM were included for initial evaluation. Existing genes were curated for new inheritance patterns where evidence existed. Curations were presented on twice monthly calls, with the HCVD GCEP composed of 29 individuals from 21 institutions across 6 countries. Results: Thirty-one genes were recurated and an additional 5 new potential HCM-associated genes were curated. Among the recurated genes, 17 (55%) genes changed classification: 1 limited and 4 disputed (from no known disease relationship), 9 disputed (from limited), and 3 definitive (from moderate). Among these, 3 (10%) genes had a clinically relevant upgrade, including TNNC1, a 9th sarcomere gene with definitive HCM association. With new evidence, 2 genes were curated for multiple inheritance patterns (TRIM63, disputed for autosomal dominant but moderate for autosomal recessive; ALPK3, strong for autosomal dominant and definitive for recessive). CSRP3 was curated for a semidominant mode of inheritance (definitive). Nine (29%) genes were downgraded to disputed, further discouraging clinical reporting of variants in these genes. Five genes recently reported to cause HCM were curated: RPS6KB1 and RBM20 (limited), KLHL24 and MT-TI (moderate), and FHOD3 (definitive). Conclusions: We report 29 genes with definitive, strong, or moderate evidence of causation for HCM or isolated left ventricular hypertrophy, including sarcomere, sarcomere-associated, and syndromic conditions.
KW - genetic testing
KW - hypertrophic cardiomyopathy
KW - sarcomere
KW - variant classification
UR - http://www.scopus.com/inward/record.url?scp=85217005901&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2024.12.010
DO - 10.1016/j.jacc.2024.12.010
M3 - Article
C2 - 39971408
SN - 0735-1097
VL - 85
SP - 727
EP - 740
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 7
ER -